Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sabina Y. van der Zanden
Immunoproteasome Inhibitor-Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin Upon Low-Dose Photon Irradiation
Journal of the American Chemical Society
Biochemistry
Colloid
Catalysis
Chemistry
Surface Chemistry
Related publications
Doxorubicin Cardiotoxicity and Target Cells: A Broader Perspective
Cardio-Oncology
Low-Molecular-Weight Polymer–drug Conjugates for Synergistic Anticancer Activity of Camptothecin and Doxorubicin Combinations
Nanomedicine
Development
Materials Science
Nanoscience
Medicine
Bioengineering
Nanotechnology
Biomedical Engineering
Dose-Escalated Total-Marrow Irradiation (TMI) for Relapsed Multiple Myeloma
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Non-Covalent Immunoproteasome Inhibitors Induce Cell Cycle Arrest in Multiple Myeloma MM.1R Cells
Journal of Enzyme Inhibition and Medicinal Chemistry
Medicine
Drug Discovery
Pharmacology
Inhibition of Exosome Release by Ketotifen Enhances Sensitivity of Cancer Cells to Doxorubicin
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Modified Bacterial Cellulose Scaffolds for Localized Doxorubicin Release in Human Colorectal HT-29 Cells
Colloids and Surfaces B: Biointerfaces
Surfaces
Colloid
Interfaces
Theoretical Chemistry
Medicine
Biotechnology
Surface Chemistry
Physical
Synthesis, in Vitro Stability, and Antiproliferative Effect of D -Cysteine Modified GnRH-doxorubicin Conjugates
Journal of Peptide Science
Organic Chemistry
Molecular Medicine
Pharmacology
Molecular Biology
Biochemistry
Structural Biology
Medicine
Drug Discovery
Hepatocellular Carcinoma Cells Surviving Doxorubicin Treatment Exhibit Increased Migratory Potential and Resistance to Doxorubicin Re-Treatment In�vitro
Oncology Letters
Cancer Research
Oncology
A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
